AzTrials
AzTrials

EGFRm Advanced Non-Small Cell Lung CancerNCT06279728

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

A study testing Datopotamab deruxtecan in people with EGFRm Advanced Non-Small Cell Lung Cancer and EGFRm Metastatic Non-Small Cell Lung Cancer, run by Daiichi Sankyo at 14 sites in United States.

Approved For Marketing

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Datopotamab deruxtecan
Type of treatment
Injection or infusion
How many people
Not given
Where
14 sitesUnited States
Study dates
Start not givento not given
Phase
Expanded access
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Who may be able to join

  • Patientsis aged ≥18 years (follow local regulatory requirements if the legal age of consent for participation is >18 years old).
  • The patient has histologically or cytologically documented advanced or metastatic NSCLC that is not amenable to curative surgery or radiation.
  • The patient must have documented AGAs in EGFR (for example, Ex19del, L858R, G719X, S768I or L861Q, either alone or in combination with other EGFR mutations, which may include T790M). Overexpression of EGFR in the absence of activating mutation is not sufficient for enrollment.
  • The patient must have progressed on at least 1 EGFR tyrosine kinase inhibitor and platinum-based chemotherapy, either combined or in either sequence.
  • The patient has adequate bone marrow reserve and organ function, based on local laboratory data, in the opinion of the treating physician.
  • If the patient is a female and of childbearing potential, a negative urine or serum pregnancy test is required at time of treatment initiation request.
Show all 13Show fewer
  • If the patient (male and female) is of reproductive/childbearing potential, they must agree to use a highly effective form of contraception or avoid intercourse during the program and upon completion of this program and for at least 7 months for females and 4 months for males after the last dose of Dato-DXd.
  • Starting at the first dose of Dato-DXd, the patient agrees that if they are:
  • A male patient, they must not freeze or donate sperm at any time during this program and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of Dato-DXd.
  • A female patient, they must not donate, or retrieve for their own use, ova at any time during this program and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of Dato-DXd.
  • The patient must have a life expectancy of >3 months as determined by the treating physician.
  • The patient is willing and able to provide written informed consent indicating that they understand the purpose of the Medical Access Program and are willing and able to participate.
  • Patients who meet any of the following criteria will not be eligible for the Medical Access Program.

Who cannot join

  • The patient has a history of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or have suspected ILD/pneumonitis that cannot be ruled out by imaging at the time of entering the program.
  • The patient has clinically severe respiratory compromise (based on treating physician assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:
  • Any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months prior to program enrollment, severe asthma, severe chronic obstructive pulmonary disease, moderate to severe restrictive lung disease, or moderate to severe pleural effusion).
  • Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis), OR
  • Prior complete pneumonectomy.
  • Patient has clinically significant unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, Grade >1 at start of treatment within the program. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the treating physician after consultation with the Sponsor Medical Approvers or designees within this program.
Show all 23Show fewer
  • Patient has active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Patient has active hepatitis C. (Active hepatitis C is defined by a positive Hep C Ab result, quantitative HCV ribonucleic acid (RNA) results greater than the lower limits of detection of the assay, and an ALT or AST greater than or equal to 2 times the upper limit of normal.)
  • Patient has uncontrolled hepatitis B. (Patients with hepatitis B [positive HBs antigen test] must meet the following criteria to be eligible: have an HBV-DNA viral load <2000 IU/mL off treatment or have an HBV-DNA viral load <2000 IU/mL on oral antiviral therapy for at least 4 weeks and during the participation in the study.)
  • The patient has known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled:
  • Undetectable viral RNA.
  • Cluster of differentiation 4 (CD4)+ count ≥350.
  • No history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).
  • If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Patients must be tested for HIV during the screening period if acceptable by local regulations or an institutional review board (IRB)/ethics committee (EC).
  • The patient has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd.
  • The patient has a history of severe hypersensitivity reactions to other monoclonal antibodies.
  • Female patient who is pregnant, breast-feeding, or intending to become pregnant.
  • The patient has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the treating physician's opinion, could affect the safety of the patient if prescribed Dato-DXd.
  • The patient has clinically significant corneal disease.
  • The patient is currently participating in or is in active follow-up (as defined by the protocol) for any Daiichi Sankyo or Astra Zeneca clinical study.
  • The patient is eligible for any available oncology clinical trial.
  • The patient has received a prior DNA topoisomerase 1 inhibitor (including as a payload of an ADC).
  • The patient has received prior radiotherapy to the brain within 2 weeks of start of Dato-DXd treatment or received radiotherapy to the chest within 4 weeks of start of Dato-DXd treatment, or the patient has ongoing radiation-related toxicities requiring corticosteroids.

Trial locations and contacts

14 sites in 1 country.

14 sites in 1 country

United States14 sites

  • University of Maryland Medical Center Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, 21201

  • Central Care Cancer Center

    Bolivar, Missouri, 65613

  • Graves Gilbert Clinic

    Bowling Green, Kentucky, 42101

  • University of Texas Southwestern Medical

    Dallas, Texas, 75390

  • Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital)

    Detroit, Michigan, 48201

  • Henry Ford Health

    Detroit, Michigan, 48202

  • Queen's Medical Center

    Honolulu, Hawaii, 96813

  • Houston Methodist Hospital Cancer Center

    Houston, Texas, 77030

  • Baptist Cancer Center

    Memphis, Tennessee, 38120

  • Touro Infirmary - LCMC Health

    New Orleans, Louisiana, 70115

  • New York Cancer & Blood Specialists

    New York, New York, 10028

  • Highlands Oncology Group

    Springdale, Arkansas, 72762

  • Overlook Medical Center Medical Diagnostic Associates Atlantic Medical Group

    Summit, New Jersey, 07901

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington, 98405

Other trials in United States

About this study

Official title: Medical Access Program for Datopotamab Deruxtecan (Dato-DXd, DS-1062a)

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical need, are unlikely to obtain optimal benefit from currently approved and commercially available drugs, and who cannot enter a suitable clinical trial.

Read the detailed description

This is a Medical Access Program that will be available to adult patients with previously treated advanced or metastatic EGFR mutated NSCLC who have no suitable treatment options and are not able to enter a clinical trial.

Patients enrolled in the Medical Access Program can continue treatment until any of the following occurs:

  • Disease progression
  • Unacceptable toxicity
  • The benefit-risk no longer favors the individual
  • Dato-DXd becomes commercially available and reimbursement is approved
  • The patient chooses to discontinue treatment
  • Withdrawal of consent
  • Pregnancy
  • Physician discretion
  • Death

Patients enrolled in the Medical Access Program have an option to participate in collection of safety-focused clinical practice data. This will contribute towards better understanding of the clinical experience of treatment with Dato-DXd. Participation in this optional data collection will have no bearing on receipt of treatment.

Being tested
Datopotamab deruxtecan
Keywords
Dato-DXd, Datopotamab, Datapotamab deruxtecan, Deruxtecan, DS-1062a, Named patient program, Emergency use, Compassionate use, Expanded access program, Medical access program, EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer, EGFR mutation, EGFR, Mutation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Datopotamab deruxtecanDrug

    Also called Dato-DXd, DS-1062a

    6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Feb 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Expanded access
IDs, dates and publications
ClinicalTrials.gov ID
NCT06279728
Sponsor's protocol ID
DS1062-0003-EAP-MA
Status last verified
Jun 2025
First submitted
19 Feb 2024
Last updated
3 Jul 2025
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing Datopotamab deruxtecan in people with EGFRm Advanced Non-Small Cell Lung Cancer and EGFRm Metastatic Non-Small Cell Lung Cancer, run by Daiichi Sankyo at 14 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06279728.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in